Mustang Bio (MBIO) Reports Preclinical Data on Regional Delivery of MB-103 HER2 CAR T Cells to Target HER2+ … – StreetInsider.com
|
Mustang Bio (MBIO) Reports Preclinical Data on Regional Delivery of MB-103 HER2 CAR T Cells to Target HER2+ …
StreetInsider.com Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced that … Mustang Bio Plans Manufacturing Facility in Worcester, MA |
